{"entity":{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","aka":[],"tldr":"The company that made BRCA testing a business, now selling hereditary panels and the myChoice, EndoPredict and Prolaris tumour tests.","summary":"Myriad held the BRCA1/2 gene patents until the 2013 US Supreme Court ruling and launched BRACAnalysis CDx (2014) and myChoice CDx (2019), the two FDA-approved companion diagnostics for PARP inhibitors. MyRisk is its hereditary cancer panel; EndoPredict (breast) and Prolaris (prostate) are its prognostic tests. Its history is a case study in how gene patents, guidelines and reimbursement shape which tests patients receive.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Myriad_Genetics","links":[{"label":"Official website","url":"https://myriad.com"}],"tags":[],"related":[],"cancers":["ovarian","breast-hr-positive","prostate"],"sections":["diagnostics","prevention"],"technologies":["germline-testing","hrd-testing","companion-diagnostic"],"targets":[],"drugs":["bracanalysis-cdx","mychoice-cdx","endopredict","prolaris"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05642780"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Salt Lake City, UT","country":"US","companyType":"diagnostics","website":"https://myriad.com","ticker":"MYGN","founded":1991,"investors":[],"funding":[]},"route":"/companies/myriad-genetics/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"},{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/"},{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/"}],"drug":[{"id":"bracanalysis-cdx","kind":"drug","name":"BRACAnalysis CDx","route":"/drugs/bracanalysis-cdx/"},{"id":"endopredict","kind":"drug","name":"EndoPredict","route":"/drugs/endopredict/"},{"id":"mychoice-cdx","kind":"drug","name":"myChoice CDx","route":"/drugs/mychoice-cdx/"},{"id":"prolaris","kind":"drug","name":"Prolaris","route":"/drugs/prolaris/"}],"trial":[{"id":"nct05642780","kind":"trial","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","route":"/trials/nct05642780/"}],"paper":[{"id":"paper-telli-hrd-score-platinum-tnbc-ccr-2016","kind":"paper","name":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","route":"/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/"}],"idea":[{"id":"idea-prostate-hrr-testing-at-metastatic-diagnosis","kind":"idea","name":"Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later","route":"/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/"}],"term":[{"id":"myriad-ruling","kind":"term","name":"Association for Molecular Pathology v. Myriad Genetics (2013)","route":"/terms/myriad-ruling/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"}]}}